Made in Europe
Partnership website: https://www.effra.eu/made-in-europe-state-play
Made in Europe is a Horizon Europe co-programmed public-private partnership running for 7 years with a budget of €1.8 billion in total. The European Factories of the Future Research Association (EFFRA) represents the private side in the partnership. Made in Europe is successor to the Factories of the Future Partnership which has been run under the Horizon 2020 programme.
Made in Europe seeks to increase the number and attractiveness of jobs in manufacturing, while securing the environmental, economic and social sustainability for future generations in Europe. The Partnership will contribute to a competitive, green, digital, resilient and human-centric manufacturing industry in Europe. It will be at the centre of a twin ecological and digital transition, being both a driver and subject to these changes. The 2030 vision for the partnership is to reinforce the global position Europe’s manufacturing industry in terms of competitiveness, productivity, and technology leadership.
Contact
Partners: EFFRA – European Factories of the Future Research Association Info@effra.eu
About EFFRA
The European Factories of the Future Research Association (EFFRA) is a non-for-profit, industry-driven association promoting the development of new and innovative production technologies.
What are partnerships?
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
How to use partnerships?
-
orientation
Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points. -
networking
Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents. -
ecosystem analysis
Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain. -
steering the agenda
Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.
Testimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
